- Home
- Solutions
- By Diseases
- Congenital Ophthalmic Diseases
- Buphthalmos
Buphthalmos is a condition characterized by the enlargement of the eyeball, typically observed in infants and young children. Protheragen, being a prominent pharmaceutical research services provider, aims to provide global buphthalmos diagnostics and therapeutic development services to international pharmaceutical companies.
Buphthalmos is usually associated with glaucoma due to its congenital origin, which is a type of glaucoma caused by developmental anomalies in the primary angle of the eye. This anomaly is characterized by abnormal development of the trabecular meshwork that is responsible for the drainage of aqueous humour. The outflow obstruction leads to elevated IOP, which in turn stretches the cornea and sclera, thus enlarging the globe. The manifestations include corneal oedema, an increase in the diameter of the cornea, and optic nerve cupping. Various genetic mutations such as those affecting CYP1B1 have emerged as some of the most important aspects of buphthalmos.
Genetic Sequencing and Mutation Analysis
Molecular diagnostics serve an important purpose in managing cases of buphthalmos. With the help of genetic sequencing methods like next-generation sequencing (NGS), causative mutations can be discovered much more efficiently. For example, roughly 20% of primary congenital glaucoma patients possess mutations within the CYP1B1 genes. These mutations can alter the development of the structures of the anterior chamber which, in turn, will result in raised intraocular pressure (IOP). More advanced sequencing technologies allow for the detection of these mutations which leads to early diagnosis and more tailored therapeutics approaches.
Functional Assays and Biomarker Identification
The evaluation of biometric parameters is important, which is even more prominent as the mutations involving alteration of genes and their roles in processes cells undergo is evaluated. For instance, the CYP1B1 mutation has been shown to disrupt the activities of the cytochrome P450 1B1 enzyme responsible for retinoic acid metabolism, resulting in pathological changes in the development of the trabecular meshwork. Moreover, the detection of markers is also important. Studies where the aqueous humour was analysed showed increased levels of some cytokines and growth factors in buphthalmos cases, which may be potential markers of disease severity.
| Therapeutics | Description | Research Stage |
| Beta-blockers | Topical beta-blockers (e.g., timolol) are used to lower intraocular pressure (IOP) by decreasing fluid production in the eye. They are often the first line of therapeutics for managing IOP in buphthalmos. | Approved |
| Carbonic Anhydrase Inhibitors | These medications (e.g., acetazolamide) can be administered orally or as eye drops to reduce fluid production in the eye, lowering IOP. | Approved |
| Prostaglandin Analogs | Prostaglandin analogs (e.g., latanoprost) enhance the drainage of aqueous humor, thereby reducing IOP. However, they are not FDA-approved for children and are used with caution in pediatric cases. | Approved |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen is at the forefront of developing innovative diagnostics and therapeutics for buphthalmos. Our comprehensive services include:
Protheragen provides specialized target identification and validation services to help clients identify and prioritize novel therapeutic targets for buphthalmos, focusing on the molecular and cellular mechanisms driving trabecular meshwork dysfunction, IOP elevation, and globe enlargement. Our services include genomic and transcriptomic analysis of buphthalmos-relevant tissues (e.g., trabecular meshwork cells, corneal endothelial cells, optic nerve tissue) and cell models, leveraging next-generation sequencing (NGS), quantitative PCR (qPCR), and single-cell RNA sequencing to identify dysregulated genes and pathways associated with CYP1B1, MYOC, and other buphthalmos-linked mutations. We conduct functional validation studies using in vitro cell models (e.g., human trabecular meshwork cells, corneal endothelial cells, retinal ganglion cells) and in vivo models to confirm the role of candidate targets in buphthalmos pathogenesis.
Preclinical models that accurately recapitulate the phenotypic and molecular features of buphthalmos—particularly in the context of immature pediatric ocular tissues—are critical for evaluating therapeutic efficacy and safety, and Protheragen specializes in the development and characterization of physiologically relevant buphthalmos models. Our services include the development of in vitro models (e.g., patient-derived induced pluripotent stem cells (iPSCs) differentiated into trabecular meshwork cells, corneal endothelial cells, and optic nerve cells; primary pediatric ocular cell cultures) and in vivo models (e.g., CYP1B1 knockout mice, MYOC mutant mice, zebrafish with trabecular meshwork defects) that mimic key buphthalmos manifestations, including elevated IOP, globe enlargement, corneal edema, optic nerve cupping, and corneal enlargement.
Protheragen offers rigorous therapeutic efficacy assessment services to evaluate the potential of novel drug candidates and therapies for buphthalmos, using our validated preclinical models. Our services are tailored to the specific therapeutic modality, whether small molecules, gene therapies, therapeutic proteins, or peptides, and include both in vitro and in vivo efficacy testing, with a focus on pediatric-relevant endpoints. For small molecule candidates targeting buphthalmos-related pathways (e.g., Rho kinase signaling, which regulates trabecular meshwork cell contractility; steroid metabolism pathways disrupted by CYP1B1 mutations), we conduct in vitro efficacy assays to assess target modulation, restoration of trabecular meshwork function, reduction of corneal edema, and protection of retinal ganglion cells.
Safety and toxicology assessment is a critical component of preclinical drug development for buphthalmos, particularly given the pediatric patient population and the need for long-term therapy. Protheragen provides comprehensive GLP-compliant safety testing services to evaluate the potential toxic effects of therapeutic candidates, with a focus on ocular and systemic safety in immature tissues. Our services include in vitro toxicology assays (cytotoxicity, genotoxicity, hemocompatibility) using buphthalmos-relevant cell models and primary pediatric ocular cells (e.g., trabecular meshwork cells, corneal endothelial cells, retinal ganglion cells), to assess the safety of candidates at the cellular level.
For in vivo toxicology testing, we use validated pediatric animal models to evaluate systemic and ocular toxicity, including assessments of ocular irritation, inflammation, corneal damage, optic nerve toxicity, and systemic organ function (liver, kidney, heart) following administration of the therapeutic candidate. Protheragen also offers pharmacokinetic (PK) and pharmacodynamic (PD) analysis services tailored to pediatric models, to characterize the absorption, distribution, metabolism, and excretion of therapeutic candidates, as well as their dose-response relationships. For gene therapies, we assess vector biodistribution to ensure targeted delivery to ocular tissues (trabecular meshwork, optic nerve) and minimize off-target effects, and evaluate immune responses to AAV vectors to address potential safety concerns. Our safety and toxicology services are designed to identify potential risks early in preclinical development, allowing clients to optimize their therapeutic candidates and ensure compliance with regulatory requirements for IND filings. By integrating efficacy and safety data, Protheragen provides clients with a comprehensive preclinical data package that supports the transition of buphthalmos therapies to clinical trials.
Protheragen prides itself on offering customized research solutions to meet the unique needs of our clients. Our team of experts works closely with clients to design and implement preclinical studies that address specific research questions and objectives. If you are interested in our services, please feel free to contact us.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.
